ArticleClinical case reports2025
Unexpected Long-Term Disease Control in Lung Cancer With Sacral Metastases After Conventional Radiotherapy and Chemotherapy Despite Discontinuation of Maintenance Therapy: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel treatments, including stereotactic body radiotherapy (SBRT), targeted therapies, and immune checkpoint inhibitors (ICIs), have improved the prognosis and outcomes of patients with metastatic lung cancer. However, not all patients are eligible for these treatments; furthermore, these novel therapies are not readily available in developing countries. We report a 54-year-old man who presented with a sacral mass, initially suspected as a chordoma and underwent subtotal resection. Further evaluation revealed a mass in the lung, confirming the pulmonary origin of the tumor. He received palliative radiotherapy (RT) to the residual sacral lesion, chemotherapy with bevacizumab, and 3D-RT to a lung lesion. Bevacizumab was discontinued after one year of maintenance therapy following a serious gastrointestinal perforation. Surprisingly, two years after stopping all treatment, he has had no sign of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.